UroGen Pharma Ltd. (URGN) |
|
9.35 0.95 (11.31%)
|
01-27 16:00 |
|
Open: |
8.4 |
Pre. Close: |
8.4 |
|
High:
|
9.67 |
Low:
|
8.4 |
|
Volume:
|
194,059 |
Market Cap:
|
216(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:48:53 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 11.29  One year: 13.19 |
| Support: |
Support1: 8.33 Support2: 7.5 |
| Resistance: |
Resistance1: 9.67 Resistance2: 11.29 |
| Pivot: |
8.41 |
| Moving Average: |
MA(5): 8.39 MA(20): 8.46
MA(100): 9.05 MA(250): 8.11 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 52.1 %D(3): 31.7 |
| RSI: |
RSI(14): 62.7 |
| 52-week: |
High: 12.63 Low: 4.84 |
| Average Vol(K): |
3-Month: 77 (K) 10-Days: 127 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ URGN ] has closed It is unclear right now based on current values. 45.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
9.69 - 9.73 |
9.73 - 9.77 |
|
Low:
|
8.3 - 8.35 |
8.35 - 8.39 |
|
Close:
|
9.26 - 9.35 |
9.35 - 9.43 |
|
Company Description |
|
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. |
Headline News |
Wed, 11 Jan 2023
UroGen Reports Results Of First Post-Commercial Utilization ... - Nasdaq
Mon, 19 Dec 2022
UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN ... - Business Wire
Fri, 09 Dec 2022
UroGen Pharma Announces Inducement Grant Under Nasdaq ... - Business Wire
Mon, 21 Nov 2022
UroGen Pharma: Jelmyto Sales Growing Steadily, Concerns ... - Seeking Alpha
Wed, 09 Nov 2022
UroGen Announces the Appointment of Dan Wildman to the UroGen ... - Business Wire
Wed, 28 Sep 2022
FDA Authorizes an Extension of the In-Use Period for UroGen ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
23 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
9.4 (%) |
|
% Held by Institutions
|
71.6 (%) |
|
Shares Short
|
673 (K) |
|
Shares Short P.Month
|
680 (K) |
Stock Financials |
|
EPS
|
-5.06 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-2.75 |
|
Profit Margin (%)
|
-175.2 |
|
Operating Margin (%)
|
-126 |
|
Return on Assets (ttm)
|
-37.4 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
41.7 |
|
Gross Profit (p.s.)
|
1.85 |
|
Sales Per Share
|
2.7 |
|
EBITDA (p.s.)
|
-3.37 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-86 (M) |
|
Levered Free Cash Flow
|
-44 (M) |
Stock Valuations |
|
PE Ratio
|
-1.86 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-3.41 |
|
Price to Sales
|
3.45 |
|
Price to Cash Flow
|
-2.52 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
